Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19약물, 대사 산물 및 폐 축적 작은 Lysosomotropic 분자: 다중 표적은 SARS-CoV-2 감염 및 COVID-19로의 진행을 방해합니다Hypothesis Published on 2021-02-112022-09-10 Journal: International Journal of Molecular Sciences [Category] MERS, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Affect approved drug approved drugs Bacterial biological characteristic candidate cathepsin cathepsin L cathepsin L-dependent characteristic Chloroquine compounds condition coronavirus coronavirus disease COVID-19 CRS cytokine Cytokine release syndrome Cytokine storm disease drug Drug repurposing drugs Effects eligibility criteria endothelial enrichment heterogeneous group host cells hydroxy Hypothesis IL-6 Inflammatory intrinsic lysosomal enzyme lysosomal enzymes lysosome Lysosomes lysosomotropism metabolite metabolites Multiple OTC pandemic Patient pharmacological profile Progress Prophylaxis pulmonary tissue pulmonary tissue accumulation receiving respiratory SARS-CoV-2 SARS-COV-2 infection second messengers severe acute respiratory syndrome Coronavirus Small molecules Stress stress response systemic inflammation targeting targets tissue transition Treatment triggered Viral viral entry viral host cell entry viral infections [DOI] 10.3390/ijms22041797 PMC 바로가기 [Article Type] Hypothesis
Clinical Characteristics and Outcome of Patients With Severe COVID-19 Pneumonia at a Public Sector Hospital in Karachi, PakistanAnesthesiology Published on 2021-02-032022-10-31 Journal: Cureus [Category] COVID-19, [키워드] Absolute lymphocyte count accounted Acute kidney injury acute respiratory distress acute respiratory syndrome Administered Admission age ARDS average Benazir Bhutto C-reactive protein cardiac complication clinical Clinical characteristics co-morbidities co-morbidity comorbid conditions complications conducted confirmed case coronavirus COVID COVID-19 Critical CRP CRS Cytokine release syndrome death demographics develop disease Factor Fever Final hospital hypertension intensive care unit Karachi lack LDH leukocyte males mechanical ventilation median moderate Mortality MOST neutrophil lymphocyte ratio NIV NLR non-invasive ventilation Non-survivors Odds ratio Older age on mechanical ventilation outcome Pakistan parameter Patient patients patients died patients with COVID-19 PCR peaked Platelet Pneumonia polymerase chain positive predominant public sector reported SARS-CoV2 Sepsis Severe COVID-19 pneumonia Shortness of breath statistically significant Steroids survival analysis Survivors Symptom syndrome the median Tocilizumab was done [DOI] 10.7759/cureus.13107 PMC 바로가기 [Article Type] Anesthesiology
Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study중증 COVID-19에 대한 토실리주맙의 초기 임상 결과: 2개 센터 후향적 연구Multicenter Study Published on 2021-02-012022-09-11 Journal: International journal of antimicrobial agents [Category] MERS, 진단, 치료제, [키워드] (coronavirus disease 2019 Analysis antigen receptor blood cell CAR chimeric antigen receptor Clinical improvement Clinical outcome Cohort conducted coronavirus disease Coronavirus disease 2019 COVID-19 Critically ill Critically ill patient critically ill patients CRS cytokine Cytokine release syndrome Day Drug administration effective Efficacy elevated evaluated had no hospital IL-6 IL-6 inhibitor Immunomodulatory agents inflammatory markers inhibitor interleukin-6 Lactate lactate dehydrogenase Lower New oxygen Patient patients patients treated primary endpoint respiratory status retrospective cohort study Retrospective study SARS-CoV-2 secondary to severe COVID-19 significantly supplemental oxygen T-cell therapy Tocilizumab tocilizumab administration treated treating COVID-19 Treatment Univariate analysis USA White blood cell with COVID-19 worsened [DOI] 10.1016/j.ijantimicag.2020.106265 PMC 바로가기 [Article Type] Multicenter Study
Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndromeCOVID-19 관련 사이토카인 방출 증후군 치료에서 IL-6 억제제의 역할Review Published on 2021-01-212022-09-12 Journal: International Journal of Medical Sciences [Category] 진단, [키워드] (Tocilizumab anti-IL-6 appear Case report classical coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients CRS cytokine Cytokine release syndrome described effective Evidence evidence of feature IL-6 IL-6 inhibitor IL-6 inhibitors information inhibiting interleukin interleukin-6 interleukin-6 inhibitor. key factor Pathogenesis pathology patients with COVID-19 rationale role sarilumab severe coronavirus disease severe COVID-19 severe COVID-19 patient severe COVID-19 patients Signaling siltuximab syndrome Therapeutics Tocilizumab trans Treatment triggering [DOI] 10.7150/ijms.53564 PMC 바로가기 [Article Type] Review
Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19Review Published on 2021-01-202022-10-30 Journal: Molecular Biomedicine [Category] COVID-19, [키워드] acute respiratory disease acute respiratory syndrome anti-viral agent Antibody Response approach caused coronavirus Coronavirus disease 2019 COVID-19 COVID-19 patients CRS Cytokine release syndrome develop Diagnosis dysregulated effective exacerbated help identify immune response immune responses Immunity immunological characteristics Immunotherapy IMPROVE lymphocyte lymphopenia management modulating multiple organ failure Pathogenesis Perspective Prognosis SARS-COV-2 infection severe COVID-19 patient spread to Treatment treatment strategy triggered understanding Vaccine viral infection virus worldwide pandemic [DOI] 10.1186/s43556-020-00015-y PMC 바로가기 [Article Type] Review
Cytokines and Chemokines in SARS-CoV-2 Infections—Therapeutic Strategies Targeting Cytokine StormReview Published on 2021-01-122022-10-28 Journal: Biomolecules [Category] COVID-19, [키워드] acute respiratory syndrome chemokine chemokines clinical development consequence Consequences coronavirus coronavirus disease COVID-19 COVID-19 infection COVID-19 infections CRS cytokine Cytokine release syndrome Cytokine storm Effects Factor hallmark host response Hyperinflammatory Infection pandemic pathophysiological Pneumonia progression SARS-CoV-2 selected Severe respiratory distress storm Strategy syndrome targeting Treatment upregulated virus [DOI] 10.3390/biom11010091 PMC 바로가기 [Article Type] Review
COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine StormOncology Published on 2021-01-082022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] Activation admitted to ICU approach approved CAR-T caused COVID-19 COVID-19 mortality COVID-19 patient CRS cytokine cytokine release deleterious effect dendritic cells evaluated events ferritin fibrosis graft-versus-host-disease hematologic hematological high mortality HLH Hospitalization hyperinflammation ICU IL-6 immune-cell Immunotherapy impacted IMPROVE Italy Jak JAK1 JAK2 janus kinase limit lymphocyte Macrophage management Migration molecular molecular mechanism multi-organ failure myelofibrosis outbreak outcome overcome pathogenic Patient Proinflammatory cytokine reducing Respiratory failure ruxolitinib SARS-CoV-2 selective Signaling solid tumor storm syndrome tissue damage TNFα treated Treatment turn virus [DOI] 10.3389/fonc.2020.599502 PMC 바로가기 [Article Type] Oncology
Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study코로나바이러스 질병-2019에 대한 치료용 혈장 교환은 사이토카인 방출 증후군을 유발했습니다. 후향적 성향 일치 대조 연구Research Article Published on 2021-01-072022-08-13 Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS, [키워드] 1:1 95% CI Analysis analyzed assigned both groups Cohort Control controls coronavirus coronavirus disease coronavirus disease-2019 COVID-19 Critical CRS cytokine cytokine release Cytokine release syndrome Cytokines discharge disease severity duration of hospitalization evaluate Forced groups hospital hospitalized patient in both group log rank male males median age moderate Mortality non-randomized objective outcome pathogenic pathophysiology Patient plasma plasma exchange polymerase chain reaction Polymerase chain reaction testing Primary outcome progression PSM reduced Result retrospective secondary Secondary outcomes selected severity significantly standard care Standard of care supportive care survival Symptom syndrome the patient Therapeutic plasma exchange TPE treated Treatment triggered Viral viral clearance was done was used with COVID-19 [DOI] 10.1371/journal.pone.0244853 PMC 바로가기 [Article Type] Research Article
Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia중증 SARS-CoV2 폐렴에서 토실리주맙의 동정적 사용Article Published on 2021-01-012022-09-11 Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 신약개발, 진단, [키워드] acute respiratory distress acute respiratory distress syndrome Administered administration age analyzed ARDS benefit C-reactive protein compassionate-use COVID-19 CRS cytokine Cytokine release syndrome D-dimer death dose drug Evolution Factor FiO2 high oxygen support High-sensitivity C-reactive protein Hospitalized hsCRP IL-6 intensive care interleukin-6 interleukin-6 receptor intravenous Intubated intubation Lymphocytes male Older age oxygen oxygen support Patient patients Pneumonia primary endpoint Prognostic factors receiving receptor antagonist required respiratory distress SARS-CoV-2 SARS-CoV-2 pneumonia SARS-CoV2 saturation severe disease severe SARS severe SARS-CoV-2 significantly syndrome TCZ Tocilizumab Treatment [DOI] 10.1016/j.ijid.2020.10.045 PMC 바로가기 [Article Type] Article
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromesCOVID-19 폭풍우를 이겨내기: 혈액학적 사이토카인 증후군의 교훈Review Published on 2021-01-012022-09-11 Journal: Blood reviews [Category] MERS, SARS, 바이오마커, 임상, 진단, [키워드] acute respiratory syndrome attenuation blockade CAR-T CAR-T cell therapy Cell Cell signaling Cell therapy Clinical features clinical trial clinical trials coronavirus COVID-19 CRS CSS cytokine cytokine level cytokine levels Cytokine release syndrome Cytokine storm syndrome cytokine syndrome Cytokines develop Diagnosis Diagnostic Criteria disease Evidence foundation hematologic hematological hemophagocytic lymphohistiocytosis idiopathic Idiopathic multicentric Castleman disease Inflammation inhibiting lesson marker multi-organ dysfunction novel Pathogenesis Patient Release respiratory SARS-CoV-2 secondary hemophagocytic lymphohistiocytosis severe acute respiratory syndrome Coronavirus Severe acute respiratory syndrome coronavirus −2 (SARS-CoV-2). severe COVID-19 sHLH signaling pathway storm subset Treatment [DOI] 10.1016/j.blre.2020.100707 PMC 바로가기 [Article Type] Review